Abingworth
Abingworth is a transatlantic life-sciences investment firm that provides capital and development expertise to biotechnology and biopharma companies. The firm invests across the company lifecycle — from seed and early-stage through clinical development and public-market positions — and operates offices in London, Menlo Park/San Francisco and Boston. Abingworth is part of Carlyle. As of 29 February 2024 the firm reported investments in 185 life-science companies, including multiple M&A transactions and IPOs.
Abingworth
Services
Equity and venture funding
Direct equity investments from Abingworth-managed funds across seed, early-stage and development-stage life-science companies.
Clinical co-development financing and execution
Structured late-stage development financing and operational partnerships through Clinical Co-Development funds and co-development companies; includes joint governance arrangements with commercial partners.
Public-equity and VIPE investing
Invests in public equities and operates Venture Investments in Public Equities (VIPE) to access value across private and public life-science companies.
Clinical development and operational support via portfolio/co-development companies
Operational drug-development, regulatory and commercialization support provided directly or through portfolio/co-development companies (examples include Launch Therapeutics and SFJ Pharmaceuticals).
Deal sourcing, strategic guidance and board-level support
Investment team provides deal origination, evaluation, active portfolio guidance and board representation across therapeutic modalities and development stages.
Equity and venture funding
Direct equity investments from Abingworth-managed funds across seed, early-stage and development-stage life-science companies.
Clinical co-development financing and execution
Structured late-stage development financing and operational partnerships through Clinical Co-Development funds and co-development companies; includes joint governance arrangements with commercial partners.
Public-equity and VIPE investing
Invests in public equities and operates Venture Investments in Public Equities (VIPE) to access value across private and public life-science companies.
Clinical development and operational support via portfolio/co-development companies
Operational drug-development, regulatory and commercialization support provided directly or through portfolio/co-development companies (examples include Launch Therapeutics and SFJ Pharmaceuticals).
Deal sourcing, strategic guidance and board-level support
Investment team provides deal origination, evaluation, active portfolio guidance and board representation across therapeutic modalities and development stages.
Portfolio
Acquired by larger pharmaceutical companies (listed among exits).
#Biopharma / Immunology
Founding investor and seed funder; incubated in Abingworth's London office. Acquired by Takeda under a previously agreed option including development and regulatory milestones.
#Immuno-oncology / Cell therapy
Provider of clinical co-development services; involved in regulatory approvals cited (e.g., BOSULIF®).
#Clinical co-development / Late-stage development financing
Partner in co-development and manufacturing services; referenced in Abingworth materials.
#Clinical development services / Co-development
Acquired by larger pharmaceutical companies (listed among exits).
#Biopharma / Immunology
Founding investor and seed funder; incubated in Abingworth's London office. Acquired by Takeda under a previously agreed option including development and regulatory milestones.
#Immuno-oncology / Cell therapy
Provider of clinical co-development services; involved in regulatory approvals cited (e.g., BOSULIF®).
#Clinical co-development / Late-stage development financing
Partner in co-development and manufacturing services; referenced in Abingworth materials.
#Clinical development services / Co-development